Xofluza (Baloxavir Marboxil) Treatment Guidelines

Primary Recommendation

Xofluza is administered as a single weight-based oral dose for treatment or prophylaxis of influenza in patients ≥12 years of age weighing >40 kg: 40 mg for patients 40-80 kg, and 80 mg for patients ≥80 kg, given within 48 hours of symptom onset or exposure. 1, 2

Age and Weight Eligibility

Xofluza is FDA-approved only for patients ≥12 years of age who weigh more than 40 kg. 1, 2

For patients weighing 40-80 kg: single 40 mg oral dose 1, 2
For patients weighing ≥80 kg: single 80 mg oral dose 1, 2
Not approved for children <12 years or <40 kg 1
No age-based dose adjustments needed for elderly patients (≥65 years)—same weight-based dosing applies 1

Treatment Indications

Xofluza should be initiated within 48 hours of symptom onset for acute uncomplicated influenza. 2, 3

High-Priority Treatment Groups (per IDSA/AAP guidelines for antivirals):

All hospitalized patients with suspected or confirmed influenza, regardless of illness duration 4
Outpatients with severe or progressive illness, regardless of timing 4
High-risk patients: children <2 years, adults ≥65 years, pregnant/postpartum women, immunocompromised patients, chronic medical conditions 4
Otherwise healthy outpatients when symptom reduction is desired, particularly within 48 hours 4

Important caveat: While IDSA guidelines (2019) recommend neuraminidase inhibitors (oseltamivir, zanamivir, peramivir) as first-line treatment 4, Xofluza represents an FDA-approved alternative with comparable efficacy to oseltamivir 2, 3. The 2024 WHO guidelines conditionally recommend baloxavir for non-severe influenza when risk of severe illness is high 5.

Prophylaxis Indications

Xofluza received FDA approval in November 2020 for post-exposure prophylaxis of influenza. 4

Prophylaxis Dosing (Identical to Treatment):

40 mg single dose for patients 40-80 kg 1
80 mg single dose for patients ≥80 kg 1
Must be initiated within 48 hours of exposure to symptomatic household contact 4

Who Should Receive Prophylaxis:

Household contacts of influenza-infected persons, especially high-risk individuals 4
Unvaccinated individuals at high risk during community outbreaks 4
Patients ≥12 years and ≥40 kg only 1

Critical note: In the Japanese trial supporting prophylaxis approval, 73% of participants started baloxavir within 24 hours of the index case's symptom onset—a timeline difficult to replicate in U.S. practice 4. Only 1% of treated household members developed influenza versus 13% with placebo 4.

Clinical Efficacy

Symptom Duration:

Median time to symptom alleviation: 50-54 hours with Xofluza versus 78-80 hours with placebo 2
No difference between Xofluza (54 hours) and oseltamivir (54 hours) in adults ≥20 years 2
Adolescents (12-17 years): 54 hours with Xofluza versus 93 hours with placebo 2

Viral Load Reduction:

Xofluza reduces viral load more rapidly than oseltamivir within 24 hours of treatment 3, 6, 7
This rapid viral suppression may reduce transmission risk, though clinical significance remains under investigation 7

Influenza B Efficacy:

Limited data in influenza B infections 2
Trial T0821: median 63 hours (Xofluza) versus 83 hours (placebo) in 24 patients 2
Trial T0831: median 93 hours (Xofluza) versus 77 hours (placebo) in 38 patients—no clear benefit demonstrated 2

Safety Profile

Xofluza is well tolerated with only mild adverse events reported. 3, 6

Common Adverse Effects:

Nausea, headache, diarrhea, bronchitis, nasopharyngitis 6
Pediatric patients (5-12 years): vomiting and diarrhea each occurred in 5% 1, 8
Overall AE incidence in children: 46.1% (Xofluza) versus 53.4% (oseltamivir) 8
No deaths, serious AEs, or hospitalizations reported in pediatric trials 8

Resistance Concerns

Emergence of variant viruses with reduced susceptibility to baloxavir has been documented, particularly in Japan where use is more common. 4, 3

Ongoing surveillance for resistance patterns is critical 4, 3
All tested influenza viruses during 2019-2020 season were susceptible to baloxavir 4
Combination therapy with neuraminidase inhibitors may help mitigate resistance concerns 7

Special Populations

High-Risk Patients:

Trial T0832 enrolled 2,182 high-risk patients (asthma, chronic lung disease, diabetes, heart disease, morbid obesity, age ≥65) 2
Xofluza demonstrated efficacy comparable to oseltamivir in this population 2

Renal Impairment:

No specific renal dose adjustments mentioned in FDA label for Xofluza 2
This contrasts with oseltamivir, which requires dose reduction for creatinine clearance <30 mL/min 4, 9

Pregnancy:

No specific data available for Xofluza in pregnancy 2
IDSA guidelines recommend neuraminidase inhibitors (oseltamivir) for pregnant women 4

Comparison to Neuraminidase Inhibitors

IDSA 2019 guidelines recommend starting treatment with a single neuraminidase inhibitor (oseltamivir, zanamivir, or peramivir) as first-line therapy. 4

Why Oseltamivir Remains First-Line:

Extensive safety and efficacy data across all age groups, including infants 4
Proven mortality benefit in hospitalized patients (OR 0.21) 9
50% reduction in pneumonia risk, 34% reduction in otitis media 4, 9
Approved for treatment and prophylaxis in patients ≥3 months (oseltamivir) versus ≥12 years (Xofluza) 4, 1

Xofluza Advantages:

Single-dose regimen improves adherence 3, 6, 8
More rapid viral load reduction than oseltamivir 3, 6, 7
Comparable symptom alleviation to oseltamivir 2, 3
Well tolerated with mild GI side effects 3, 6, 8

Common Pitfalls to Avoid

Do not prescribe Xofluza to patients <12 years or <40 kg—it is not FDA-approved for this population 1, 2
Do not delay treatment while awaiting laboratory confirmation in high-risk or severely ill patients—empiric treatment based on clinical suspicion is appropriate 4, 10
Do not withhold treatment if patient presents beyond 48 hours with severe, progressive, or high-risk features—antiviral benefit persists up to 96 hours in hospitalized patients 4, 9
Do not confuse treatment dosing with prophylaxis dosing—Xofluza uses the same single weight-based dose for both indications 1
Do not assume Xofluza is superior to oseltamivir—efficacy is comparable, and oseltamivir has more extensive safety data and broader age approval 4, 2
Do not use Xofluza as first-line in pregnant women—oseltamivir is preferred due to established safety profile 4

Clinical Decision Algorithm

Step 1: Confirm Eligibility

Age ≥12 years AND weight >40 kg?
- Yes → Proceed to Step 2
- No → Use oseltamivir (weight-based dosing available for all ages ≥3 months) 4

Step 2: Assess Timing

Symptom onset or exposure within 48 hours?
- Yes → Proceed to Step 3
- No, but patient is hospitalized/severely ill/high-risk → Consider oseltamivir (proven benefit up to 96 hours) 4, 9

Step 3: Choose Antiviral

Xofluza: 40 mg (40-80 kg) or 80 mg (≥80 kg) single dose 1, 2
Oseltamivir: 75 mg twice daily × 5 days (standard alternative) 4
Consider oseltamivir first-line if: pregnant, <12 years, severe illness requiring proven mortality benefit, or concern for adherence with 5-day course is not an issue 4

Step 4: Patient Counseling

Take Xofluza as a single dose—no additional doses needed 2, 3
Can be taken with or without food 2
Expect symptom improvement within 50-80 hours 2
Vaccination remains the primary prevention strategy—antivirals are not a substitute 4

What is the recommended treatment with Xofluza (baloxavir marboxil) for a patient with confirmed or suspected influenza, considering age, weight, and medical history?

Help us tailor your experience